Based on mRNA expression data, Beuselinck et al. performed a clustering analysis and identified four molecular subgroups of ccRCC, even if done in a cohort of patients receiving sunitinib: ccrcc1 (“c-myc-up”), ccrcc2 tumors (“classical”), ccrcc3 (“normal-like”) and ccrcc4 tumors (“c-myc-up and immune-up”). This evidence concerns the gene MYC and nonpapillary renal cell carcinoma.